AIP
BIIB icon

Arrowpoint Investment Partners’s Biogen BIIB Stock Holding History

Arrowpoint Investment Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Buy
6,838
+2,132
+45% +$408K 0.32% 45
2026
Q1 		$863K Buy
4,706
+1,851
+65% +$341K 0.77% 28
2025
Q4 		$502K Buy
+2,855
New +$466K 0.07% 72
2025
Q2 		– Sell
-4,763
Closed -$652K – 158
2025
Q1 		$652K Buy
+4,763
New +$681K 0.08% 303

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowpoint Investment Partners's BIIB Position: Q2 2026 in Review

Arrowpoint Investment Partners increased its Biogen (BIIB) stake by 45% in Q2 2026, buying an estimated $408K and bringing the position to 6,838 shares worth $1.48M. The position accounts for 0.32% of the portfolio, ranked #45.

Arrowpoint Investment Partners first reported a position in BIIB in Q1 2025 and has held it in 4 quarters since. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Arrowpoint Investment Partners held 6,838 shares of Biogen worth $1.48M as of Q2 2026.
  • Arrowpoint Investment Partners bought 2,132 Biogen shares in Q2 2026, an estimated $408K.
  • Biogen made up 0.32% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #45 holding.
  • Arrowpoint Investment Partners first reported a position in Biogen in Q1 2025 and has held it in 4 quarters since.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.